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Abstract
Background: Thyrotropin-producing pituitary tumor is relatively rare. In particular, concurrent cases associated with
Graves’ disease are extremely rare and only nine cases have been reported so far. We describe a case of a
thyrotropin-producing pituitary adenoma concomitant with Graves’ disease, which was successfully treated.
Case presentation: A 40-year-old Japanese woman presented with mild signs of hyperthyroidism. She had positive
anti-thyroid-stimulating hormone receptor antibody, anti-thyroglobulin antibody, and anti-thyroid peroxidase
antibody. Her levels of serum thyroid-stimulating hormone, which ranged from low to normal in the presence of
high levels of serum free thyroid hormones, were considered to be close to a state of syndrome of inappropriate
secretion of thyroid-stimulating hormone. Magnetic resonance imaging showed a macropituitary tumor. The
coexistence of thyrotropin-producing pituitary adenoma and Graves’ disease was suspected. Initial therapy included
anti-thyroid medication, which was immediately discontinued due to worsening symptoms. Subsequently, surgical
therapy for the pituitary tumor was conducted, and her levels of free thyroid hormones, including the thyroid-
stimulating hormone, became normal. On postoperative examination, her anti-thyroid-stimulating hormone
receptor antibody levels decreased, and the anti-thyroglobulin antibody became negative. The coexistence of
thyrotropin-producing pituitary adenoma and Graves’ disease is rarely reported. The diagnosis of this condition is
complicated, and the appropriate treatment strategy has not been clearly established.
Conclusions: This case suggests that physicians should consider the coexistence of thyrotropin-producing pituitary
adenoma with Graves’ disease in cases in which thyroid-stimulating hormone values range from low to normal in
the presence of thyrotoxicosis, and the surgical treatment of thyrotropin-producing pituitary adenoma could be the
first-line therapy in patients with both thyrotropin-producing pituitary adenoma and Graves’ disease.
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Background
Thyrotropin-producing pituitary adenoma (TSHoma) is
a very rare disease, representing less than 1% of all pitu-
itary tumors [1, 2]. Graves’ disease is a common auto-
immune endocrinological disorder. Although these
diseases manifest similar symptoms of thyrotoxicosis,
the treatment for each disease is very different. Up to
now (August 2016), nine cases of TSHoma associated
with Graves’ disease have been reported [3–10]. In some
of those reports, the coexistence of these two diseases
made the diagnosis and treatment complicated; thus,
thyrotoxicosis was insufficiently controlled. Here we de-
scribe an extremely rare case of TSHoma simultaneously
existing with Graves’ disease in which an anti-thyroid
drug exacerbated the patient’s symptom; however, pituit-
ary surgery was successful.
Case presentation
A 40-year-old Japanese woman presented to a hospital
because of a headache in 2004. A magnetic resonance
image (MRI) showed one adenoma on her pituitary
gland that measured 4×7 mm. Her levels of pituitary an-
terior lobe hormones were normal. Thus, the tumor was
thought to be non-functioning. Thereafter, the tumor
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was followed yearly with MRI to determine whether it
was growing. In September 2009, periodic MRI showed
that the pituitary tumor had become larger. She was re-
ferred to our hospital for further evaluation. She had no
remarkable history or medications. She had a family his-
tory of rheumatoid arthritis. On physical examination,
her blood pressure was 127/75 mmHg, and her pulse
was regular at 105 beats/minute. Her body temperature
was 36.8 °C, height was 163.7 cm, body weight was
53.8 kg, and body mass index was 20.1 kg/m2. Her con-
sciousness was alert. She had no neck goiter or leg
edema. Both Achilles’ tendon reflexes were moderately
increased. She had mild exophthalmos. She denied any
headaches or visual field defect. Her other clinical symp-
toms were not notable. An endocrinological examination
and thyroid echocardiography were performed because
of hyperthyroidism; in particular, Graves’ disease was
suspected. Her serum free triiodothyronine (FT3) level
was 6.3 pg/mL (normal 2.3 to 4.0 pg/mL), free thyroxine
(FT4) level was 2.3 ng/dL (normal 0.9 to 1.7 ng/dL),
thyroid-stimulating hormone (TSH) level was 0.27 μIU/
mL (normal 0.5 to 5.0 μIU/mL), anti-TSH receptor anti-
body (TRAb) was positive (5.0 IU/L, normal <1.0 IU/L),
anti-thyroglobulin antibody (TgAb) was positive (2.3 IU/
mL, normal <0.3 IU/mL), and anti-thyroid peroxidase
antibody (TPOAb) was positive (4.6 IU/mL, normal
<0.3 IU/mL). Ultrasonography showed a moderately
hypervascular thyroid without any nodes. Due to the in-
crease in her FT3 and FT4 levels, and the decrease in
her TSH level and TRAb positivity, Graves’ disease was
diagnosed, and anti-thyroid drug therapy was started in
April 2010. Subsequently, she stopped taking her medi-
cation because she felt that the headache and sweating
were exacerbated. In Graves’ disease, the TSH level is
normally suppressed by negative feedback due to an in-
crease in the FT3 and FT4 levels; the TSH value falls
below the detectable level (<0.1 μIU/mL according to
second-generation TSH chemiluminometric assays). In
our case, our patient’s TSH value ranged from 0.1 to 0.5
for the 6 months before she started the medication. We
suspected that this case was close to being in a state of
syndrome of inappropriate secretion of TSH (SITSH), al-
though in SITSH, the TSH values are generally
increased.
The simultaneous coexistence of TSHoma was highly
suspected. A pituitary MRI showed a less enhanced area
in the sella turcica (10×13 mm). On graphical examin-
ation, the tumor appeared to be slightly invading her
right lateral cavernous sinus (Fig. 1). An anterior pituit-
ary hormone stimulation test indicated that only the
TSH had an impaired response to a TSH-releasing hor-
mone (TRH) stimulation test.
Endoscopic trans-sphenoidal neurosurgery was per-
formed for the pituitary adenoma in January 2011. Im-
mediately postoperatively, her TSH values decreased
below the detection limit (<0.1 μIU/mL) [11], and her
FT3 and FT4 levels became within normal range. A
histological examination showed that immunostaining
was 99% positive for TSH-β (Figs. 2 and 3). Postopera-
tively, her TSH levels gradually became normal, and her
FT3 and FT4 levels did not increase until February 2016.
Her symptom disappeared. TRAb continued to be posi-
tive; however, her level of TRAb decreased. TgAb be-
came negative, whereas TPOAb continued to be
positive.
Discussion
TSHomas are a rare cause of hyperthyroidism, and they
account for less than 1% of all pituitary adenomas [1, 2,
10]. They often manifest with mild symptoms of thyro-
toxicosis, and they are associated with abnormal levels
of thyroid hormones and TSH [10]. Although the levels
Fig. 1 Imaging study. a T1-gadolinium magnetic resonance imaging on admission showing a less enhanced area in the sella turcica, which
seemed to be a macroadenoma (10×13 mm). b The tumor slightly invaded the right lateral cavernous sinus
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Fig. 2 Levels of the anti-thyroid-stimulating hormone receptor antibody, thyroid-stimulating hormone, and free thyroxine. The free thyroxine level
was above 1.5 ng/dL preoperatively. Total resection of the pituitary adenoma by endoscopic trans-sphenoidal neurosurgery was performed in
January 2011. The free thyroxine level decreased within normal range. Subsequently, the euthyroid status was maintained. In the meantime, the
thyroid-stimulating hormone values ranged from 0.1 to 0.5 μIU/mL preoperatively. The thyroid-stimulating hormone value of a typical patient with
Basedow’s disease is less than 0.1 μIU/mL. In the case of syndrome of inappropriate secretion of thyroid-stimulating hormone, the thyroid-
stimulating hormone value is more than 0.5 μIU/mL. The present case did not fit either of these two diseases. On postoperative examination, the
thyroid-stimulating hormone value decreased below the detection threshold. Gradually, the thyroid-stimulating hormone values became normal.
Anti-thyroid-stimulating hormone receptor antibody was continuously above the upper limit of normal range. FT4 free thyroxine, TRAb anti-thyroid-
stimulating hormone receptor antibody, TSH thyroid-stimulating hormone
Fig. 3 Pathological diagnosis of pituitary adenoma was determined (a). Immunostainning showed the following: thyroid-stimulating horomone,
strongly positive (b); follicle stimulating hormone, weakly positive; luteinizing hormone, negative; growth hormone, focally positive: prolactin,
focally positive; and adenocotrophic hormone, negative
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of FT3 and FT4 increase, the TSH levels are not sup-
pressed. This state is defined as SITSH [12]. In general,
SITSH indicates the possibility of TSHoma and syn-
drome of resistance to thyroid hormone (RTH). The
mechanism of RTH is a thyroid hormone receptor (TR)-
β deficit. We analyzed the TR-β mutations of our pa-
tient, but they were negative. On postoperative examin-
ation, her TSH values decreased below the detection
limit, and histological examination showed that immu-
nostaining was 99% positive for TSH-β. The present case
could definitely be diagnosed as having TSHoma. How-
ever, two points were unusual in our case. First, our pa-
tient was TRAb positive. TRAb provokes the TSH
receptor and produces more amounts of the thyroid
hormone than that of a healthy person. The determin-
ation of TRAb and exophthalmos found on the initial
examination provided definite evidence for Graves’ dis-
ease [10]. Second, preoperatively, the TSH levels in our
case ranged from normal to low, although in typical
cases of SITSH, they range from normal to high [13,
14]. We consider that this obscure value is the result of
concomitant Graves’ disease, and hyperthyroidism in
this case was attributed to both TSHoma and Graves’
disease.
TSHoma associated with Graves’ disease is extremely
rare. We searched PubMed for cases of TSHoma associ-
ated with autoimmune hyperthyroidism, Graves’ disease.
Only nine cases (written in English) have been reported
so far (August 2016) [3–10]. In four cases, TSHoma pre-
ceded the occurrence of Graves’ disease [3, 4, 6, 7]. In
two cases, Graves’ disease occurred prior to the onset of
TSHoma [8, 9]. In the other three cases, Graves’ disease
and TSHoma probably coexisted at the initial diagnosis,
as in our case [5, 8, 10].
The treatment for TSHoma concomitant with Graves’
disease is complicated, because the treatment of Graves’
disease is very different from that of TSHoma. As previ-
ously mentioned, three cases with both TSHoma and
Graves’ disease have been reported. In all these cases,
anti-thyroid medication was chosen first to treat Graves’
disease. However, the medication failed to normalize the
FT4, FT3, and TSH levels, resulting in the progression
of TSHoma. The reason for this is because anti-thyroid
therapy inhibits negative feedback to TSH, just as anti-
thyroid medication administered under a misdiagnosis
of Graves’ disease may carry the risk of promoting
TSHoma due to the positive feedback system [15].
Therefore, anti-thyroid therapy should not be considered
the first-choice treatment in patients with both TSHoma
and Graves’ disease.
In our case, anti-thyroid medication was started first;
however, our patient soon discontinued the medication
of her own accord. Eventually, TSHoma was successfully
treated by endoscopic trans-sphenoidal neurosurgery.
Subsequently, her TSH value decreased below the de-
tectable minimum limit, and it gradually normalized.
Her FT3 and FT4 levels became normal immediately
postoperatively. Her subjective symptom disappeared. Of
interest, her TRAb levels decreased, TgAb became nega-
tive, and Graves’ hyperthyroidism has not occurred since
the operation. The cause of postoperative remission of
Graves’ hyperthyroidism is not clear. However, these ob-
servations suggest that the treatment for TSHoma might
have improved Graves’ hyperthyroidism in our case,
although the most probable explanation was considered
to be that Graves’ disease became euthyroid state
spontaneously.
TSH plays an important role in the maintenance of
normal physiology and in the regulation of immuno-
modulatory gene expression of thyrocytes [7]. One ex-
planation for these observations is that the abnormal
hypersecretion of TSH can produce anti-idiotypic anti-
bodies, causing Graves’ disease [6], and the normalization
of TSH secretion by treating TSHoma may reduce the
production of those antibodies and thus improve Graves’
hyperthyroidism.
In any case, the surgical treatment of TSHoma may be
considered the first choice in patients with both
TSHoma and Graves’ disease to prevent the risk of pro-
moting TSHoma by anti-thyroid therapy. Conversely,
some reports have shown that Graves’ disease has subse-
quently occurred after TSHoma is treated. In one case,
it was suggested that a rapid reduction in the TSH levels
postoperatively induced apoptosis and activated an auto-
immune response against the thyroid gland. The mech-
anism is the increased expression of various cell surface
markers on thyrocytes [7]. Hence, physicians should pay
attention to the development of Graves’ disease after
TSHoma is treated, especially in cases with concomitant
Graves’ disease.
Conclusions
The present case demonstrated that trans-sphenoidal
surgery, which is the standard therapy for TSHoma,
should be considered first-line therapy in patients with
both TSHoma and Graves’ disease. Then, when Graves’
disease becomes active, anti-thyroid therapy should be
started as second-line therapy. Moreover, a definitive op-
eration is needed to prevent the subsequent treatment
from becoming complicated.
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